trending Market Intelligence /marketintelligence/en/news-insights/trending/lirrH-PmHcRy7cdfit4Tig2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Bellicum Pharmaceuticals plans concurrent offerings to raise up to $123M

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Bellicum Pharmaceuticals plans concurrent offerings to raise up to $123M

Bellicum Pharmaceuticals Inc. said it plans to raise $53 million in an offering of preferred stock and warrants to the market, and a further $70 million following negotiations with certain institutional investors.

The Houston-based immunotherapy developer is planning to sell series 1 preferred stock in the public offering to raise about $53 million. Each preferred stock will be sold together with a seven-year warrant to buy 100 common shares.

The warrants are immediately exercisable. In some instances, a warrant holder will be able to buy one series 1 preferred stock instead of the common shares.

Jefferies and Wells Fargo Securities are acting as the book-running managers for the public offer.

Bellicum also plans to enter an agreement directly with investors to sell series 2 and series 3 preferred stock, and related warrants to buy common shares, for total proceeds of $70 million.

The private placement will have two or more separate closings, each at the option of the investors and subject to conditions, Bellicum said in a news release. The company said it expects the investors to pay an up-front option fee of about $12 million.

Bellicum Pharmaceuticals develops immune therapies for treating blood cancers, solid tumors and orphan inherited blood disorders. Its chimeric antigen receptor T cell therapy called BPX-601 previously showed promise in an early-stage study in patients with advanced pancreatic cancer.

CAR-T therapies involve taking a person's own immune cells and modifying them to fight cancer cells when infused back into the body.